ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain MetastasesPriya Kumthekar, Nuhad K. Ibrahim, Shou‐Ching Tang et al.|Clinical Cancer Research|2020Cited by 242
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patientsEudocia Q. Lee, Patrick Y. Wen, Matthias Holdhoff et al.|Neuro-Oncology|2020Cited by 40
LTBK-08. TOCA 511 & TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMATimothy F. Cloughesy, Michael A. Vogelbaum, Kevin Petrecca et al.|Neuro-Oncology|2019Cited by 17
Investigating the Relationship Between Radiation Dose to Neural Stem Cell Niches and Survival in GBMAudrey Rizzo, Shih‐Chi Chao, John S. Yu et al.|International Journal of Radiation Oncology*Biology*Physics|2014Cited by 4
Efficacy and safety of pembrolizumab in combination with olaparib in previously treated recurrent cervical cancer: An open-label, single-arm, phase II studyJohn P. Diaz, Manmeet S. Ahluwalia, E.D. Schroeder et al.|Gynecologic Oncology|2025Cited by 0